Jellagen Pty Ltd appoints Galvin Mould to the Board as Chairman
Jellagen Pty Ltd, a new medical technology and healthcare
company, is pleased to announce the appointment of Galvin Mould as
its new Chairman.
Galvin succeeds David Evans, an
entrepreneurial investor and Chairman
in many companies, who stepped down earlier this
year as the company's founding Chairman.
Galvin Mould is
a senior executive
with an accomplished
background in medical
technology manufacturing, sales, marketing and general management.
Galvin has extensive experience in medical device companies,
most recently as President-International at
Orthofix. Previous to this Galvin held a number
of senior management positions at Zimmer and Biomet. He is also
currently Chairman of two other medical tech companies.
Jellagen was founded in May 2013 by 2 highly experienced
entrepreneurs Alex Muhlholzl and Andrew Mearns Spragg and secured
its first round funding of £550,000 in April 2014 from Finance
Wales and Angel investors. The Company
aims to be the world's first
provider of pharma grade, GMP and ISO
certified Type II and Type V jellyfish collagen as a raw material.
The company's initial target market for its
non-mammalian collagen product is the
lucrative cell culture reagent market
valued globally at US$14.7Bn in 2013 (Markets &
Markets 2014) with future ambitions in bone health and wound
healing medical applications for its collagen products.
The company offers the full spectrum of jellyfish derived
collagen proteins, mainly Type II - Type V, with others available,
as well as a range of additional products in development for derma
care and medical device applications. Collagen is used in the
manufacture of biomaterials due to its ability to form strong
fibres and used in many forms,
including gels scaffolds, and
membranes, for a number of medical
applications ranging from wound care and cartilage repair through
to bone grafts.
Jellagen operates from a
processing facility in Pembrokeshire,
Wales with its medical grade product
being produced by its strategic partner Collagen Solutions Plc,
Andrew Mearns Spragg, the
Company's Co-Founder & Chief
Executive Officer said "Alex and
I are delighted with the appointment. Galvin's track record
and contact network in the bone health market and more broadly in
the regulatory process for medical devices will be of huge benefit
to the company. We look forward to working with Galvin over the
coming months and years to help guide and develop our non-mammalian
sourced collagen products for a range of bone health and other
Alex Muhlholzl the Company's Founder
and Chief Technology Officer added:
"We would also like to thank Mr David Evans for
his considerable early support in the company's development plans
and also appreciate his commercial guidance
during the early days of
Jellagen's creation and fund raising
activities. We are pleased to maintain an association with David
through our partnering with Collagen Solutions Plc
and look forward to working
with David and the Collagen
Solutions team for years to come."
Galvin Mould said "I am pleased to be joining
Jellagen at this exciting stage in the
development and commercialisation of this
new source of collagen, which
offers so many advantages in a
number of medical applications. I look forward to working
with Andrew, Alex and the Jellagen team and contributing to the
growth and success of this outstanding business"